About 2.3 million people are diagnosed with breast cancer worldwide each year, making it the most commonly diagnosed cancer on the planet. In the United States alone, an estimated 382,640 women will receive a breast cancer diagnosis in 2026, including both invasive and non-invasive forms. These numbers have been climbing gradually, driven by a mix of better screening detection and genuine increases in incidence.
Global Numbers at a Glance
The International Agency for Research on Cancer reported 2.3 million new breast cancer cases and 670,000 breast cancer deaths worldwide in 2022, the most recent year with complete global data. Those cases are not evenly distributed. Incidence rates vary nearly fourfold depending on where you live. Australia and New Zealand have the highest rates at about 95.5 cases per 100,000 women, followed closely by Western Europe (90.7) and North America (89.4). The lowest rates are found in South-Central Asia (26.2), Middle and Eastern Africa (33), and Central America (39.5).
These gaps reflect differences in screening access, reproductive patterns, obesity rates, and hormone therapy use. Countries with widespread mammography programs detect more early-stage cancers, which inflates their incidence numbers even as it improves survival. In lower-income regions, many cases go undetected or are diagnosed late, so the true burden is likely higher than the numbers suggest.
United States Estimates for 2026
In the U.S., an estimated 321,910 women will be diagnosed with invasive breast cancer in 2026, where cancer cells have grown beyond the milk ducts or lobules into surrounding tissue. Another 60,730 women will be diagnosed with non-invasive breast cancer, primarily ductal carcinoma in situ (DCIS), where abnormal cells are confined within the ducts. Combined, that brings the total to roughly 382,640 female diagnoses.
Men account for a small but real share: approximately 2,670 men will be diagnosed with invasive breast cancer in 2026. That works out to about 1 in every 100 breast cancer diagnoses in the U.S. occurring in a man.
Who Gets Diagnosed and at What Age
Breast cancer risk rises sharply with age. The median age at diagnosis for women in the U.S. is 63, meaning half of all cases occur before that age and half after. Cases in women under 40 are relatively uncommon but tend to be more aggressive when they do occur. The bulk of diagnoses happen between ages 55 and 74.
Incidence rates also differ by race and ethnicity. Non-Hispanic white women have the highest overall rate at about 141 per 100,000, followed by non-Hispanic Black women at 132 per 100,000 and non-Hispanic Asian/Pacific Islander women at about 117 per 100,000. Hispanic women have the lowest rate at roughly 108 per 100,000. These figures come from the SEER program’s most recent five-year data (2019 to 2023). One critical detail: although Black women are diagnosed at a slightly lower rate, they die from breast cancer at significantly higher rates, largely because of differences in tumor biology, later-stage diagnosis, and unequal access to timely treatment.
Stage at Diagnosis
The stage at which breast cancer is caught makes an enormous difference in outcomes. CDC data from 2018 to 2022 shows that about two-thirds (66.5%) of female breast cancers in the U.S. are found at a localized stage, meaning the cancer has not spread beyond the breast. Roughly one in four (25.2%) are found at a regional stage, where cancer has reached nearby lymph nodes or tissues. Six percent are diagnosed at a distant stage, meaning the cancer has already spread to other parts of the body like bones, lungs, or the liver. The remaining 2.3% have an unknown stage at the time of reporting.
Localized breast cancer has a five-year relative survival rate above 99%, which is why screening and early detection efforts receive so much emphasis. Regional-stage cancers still have strong survival rates, though treatment is more intensive. Distant-stage breast cancer has a markedly lower survival rate, which is why the 6% figure, while small in percentage terms, represents tens of thousands of women each year facing a far more difficult prognosis.
How Rates Vary Around the World
The nearly fourfold gap in breast cancer rates between high-income and low-income regions is one of the starkest patterns in global cancer data. In wealthier countries, several factors push rates higher: earlier onset of menstruation, later age at first pregnancy, fewer pregnancies overall, higher rates of obesity, greater use of hormone replacement therapy, and widespread screening that catches cancers that might never have caused symptoms.
In lower-income countries, rates are rising. Urbanization, shifting diets, declining birth rates, and increasing body weight are all contributing. At the same time, many of these regions lack the screening infrastructure and treatment capacity to manage the growing caseload. The result is a troubling pattern: incidence is climbing toward the levels seen in wealthy nations, but survival rates remain far lower. The IARC projects that both new cases and deaths will continue to increase globally in the coming decades, with low- and middle-income countries bearing a disproportionate share of the burden.
Invasive vs. Non-Invasive Breast Cancer
Not all breast cancer diagnoses carry the same weight. Invasive breast cancer, which accounts for about 84% of U.S. diagnoses, means abnormal cells have broken through the lining of the ducts or lobules and can potentially spread. This is what most people picture when they think of breast cancer, and it’s the type that requires the most aggressive treatment.
Non-invasive breast cancer, mostly DCIS, is detected almost entirely through mammography. These abnormal cells haven’t spread and may never become life-threatening. About 60,730 cases of non-invasive breast cancer are expected in the U.S. in 2026. The detection of DCIS has become somewhat controversial in cancer medicine because treatment (often surgery and radiation) can be intensive for a condition that, in many cases, would not have progressed. Still, because there’s no reliable way to predict which cases of DCIS will become invasive, most are treated.